Zilebesiran, a ribonucleic acid interference agent targeting angiotensinogen, proves a promising approach in hypertension
- PMID: 39222421
- DOI: 10.1093/cvr/cvae140
Zilebesiran, a ribonucleic acid interference agent targeting angiotensinogen, proves a promising approach in hypertension
Keywords: Angiotensinogen; Gene silencing; Hypertension; Medication adherence; RNA interference.
Conflict of interest statement
Conflict of interest: Professor Webb’s employer, the University of Edinburgh, has been paid by Alnylam for his contributions to the zilebesiran programme in hypertension. He has undertaken recent consultancy roles with Idorsia, Janssen, and Silence pharmaceuticals in the field of cardiovascular research.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical